Pfizer expects 2021 sales of the Covid-19 vaccine it developed with German partner BioNTech to reach $36bn (€31bn) and forecast another $29bn from the shot in 2022, topping analyst estimates for both years.
The US drugmaker said it is seeking to sign more vaccine deals with countries, which could drive sales even higher next year. It has the capacity to produce 4 billion doses in 2022 and has based its projections on sales of 1.7 billion doses.
The vaccine brought in sales of $13bn in the third quarter. The company splits gross profit from sales of the shot in most of the world with BioNTech.
Pfizer's Covid-19 vaccine was the first to receive US authorisation last year, and US regulators are likely to give the green light to begin administering it to children aged five to 11 this week.
Pfizer's updated vaccine sales forecast suggests the shot will account for as much as 44% of its total revenue for the year.
Analysts have said that Pfizer and other Covid-19 vaccine makers stand to reap billions of dollars from annual vaccine boosters over the next few years.
Company executives said Pfizer plans to monitor participants in its clinical study for a fourth dose, to document the impact of possible annual, repeat vaccinations.